Therapeutics: CXC chemokine receptor 4 (CXCR4; NPY3R); lymphocyte-specific protein kinase (LCK) Provisional patent application filed; available for licensing
By BC Staff | Mar 19, 2015 | 7:00 AM GMT
Autoimmune disease
INDICATION: Autoimmune disease
In vitro studies suggest an antibody-drug conjugate (ADC) targeting CXCR4 and LCK could help treat autoimmune
Read the full 195 word article
